DSU DSU
Company Profile ↓Company Overview
DSU (DSU) is a publicly traded company listed on with a market capitalization of $530.28M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 9.3.
Maintains a net profit margin of 98.8%.
Carries low leverage with a debt-to-equity ratio of 0.18.
Recent Developments
- Dec 2025 Revenue of $39.19M (-12.0% YoY); net profit $38.71M.
- Trailing 12 Months Year-on-year growth — revenue -12.0%, earnings -12.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -12.02% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -12.09% |
Stock Price Performance
| 1 Year: | -6.43% |
| 6 Months: | -8.24% |
| 3 Months: | -5.95% |
| 1 Month: | -3.28% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)29.29 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 98.8%.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | -19.44M | 70.04M | 44.55M | 39.19M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 298.66K | 431.09K | 520.39K | 487.21K |
| Operating Income | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| Interest Expense | - | 5.30M | 8.35M | 7.90M | 5.62M |
| Pretax Income | - | -19.74M | 69.61M | 44.03M | 38.71M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -19.74M | 69.61M | 44.03M | 38.71M |
| Diluted EPS | 0.74 | -0.42 | 1.50 | 0.92 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 654.74M | 667.64M | 671.32M | 762.27M |
| Current Assets | - | - | - | - |
| Cash & Equivalents | 4.02M | 0 | 3.22M | 2.29M |
| Inventory | - | - | - | - |
| Receivables | 11.01M | 10.18M | 12.33M | 7.87M |
| Total Liabilities | 168.17M | 160.24M | 120.66M | 131.47M |
| Current Liabilities | - | - | - | - |
| Long Term Debt | - | - | - | - |
| Total Debt | 164.00M | 149.63M | 102.00M | 113.00M |
| Total Equity | 486.57M | 507.40M | 550.66M | 630.80M |
| Shares Outstanding | 46.61M | 46.61M | 51.81M | 62.24M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 119.60M | 59.01M | 52.13M | -53.89M |
| Investing Cash Flow | - | - | - | - | - |
| Financing Cash Flow | - | -119.19M | -63.14M | -49.20M | 53.18M |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | 119.60M | 59.01M | 52.13M | -53.89M |
| Net Change in Cash | - | 406.46K | -4.13M | 2.94M | -709.18K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | 101.5% | 99.4% | 98.8% | 98.8% |
| ROE % | - | -4.1% | 13.7% | 8.0% | 6.1% |
| ROCE % | - | - | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DSU
Blackrock Debt Strategies Fund (DSU) Stock Price, News & Analysis - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE5oZFFnVEVndjZJdmdReXBNM0x4R0g4dm5CcE9CSDR0QzVleDdGWHZZQkFBU3RUWmdHbkFQdjVRQ1NsRExkYlEySVhadmZJU0s1eEE?oc=5" target="_blank">Blackrock Debt Strategies Fund (DSU) Stock Price, News &…
Understanding Momentum Shifts in (DSU) - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPTTcwcXRRWGIzd2FZLXZUeDJXZlhPanRabDA4SHFCVnNEcVUzQm85NkNwc3JiUjk0endaTmxSbGdxQzhXSEc5NjdoSUVMUG5UQ2N6WnA5M0l5cTQtbGNYZEZ2WHc3TzNqcmhacWFqVmlBMGJTam5GeXpWMjVMc01IbmNGQzA5bTFackNhdU…
BlackRock Debt Strategies Fund (NYSE:DSU) Hits New 1-Year Low - Here's What Happened - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOeE5ta3FrZmM0STFRY1hlb3F5TnFYVmJjSUI5TjJyUHRzUFdZLVg1WVVYWjdNcV9Ldk4yaHNfbEJWWXRFTUhjWGpnQjY3TU1mQmRBWnlxcXNkbGUtUmZuWUtOTkVhZ2dOV1doQWF6Vzg1LUo5NzlYREVYRGtST0dZLXFKc2h5U2haQkx1Y0…
DSU: Dividend Needs To Be Reduced Or The NAV Will Suffer (Rating Downgrade) (NYSE:DSU) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQM0VyRUt6bEJZMnhubDJUd0VuY1NoX1RZS0U1eHh5aVA0dXBsZmRJcmtMYXlHa2VXM3NscVpSZTRSbmxYMWVtMDhqMjhwWjZ0WXY2cjM3RVBTV3FrNkdIejNEUWZmRWd0SE1vNU41cElocFRjT2VEVDJrdWRueWdIenBaTFdWMnowcENLdk…
BlackRock Debt Strategies Fund yields 13.7% but trades at a 6.7% discount amid interest rate risks - Pluang
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPNHlGbkYxbVB2dVNtUUtsWVBJYkJaMENPb1lQRmE5ODk1NzJCeWpwTHBydktIUzM1LVJWbDhFQjlKeDhLSEU1bms2OXBJb2FTaHp4ejRqeWFWYnd4TmdnVl81ajNtazdTbzNOZHMxbHA3dkRvRFhoT3VHNnNqM3RMQ1hhdXExc3BBRlFvdT…
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for D - InvestorNews
<a href="https://news.google.com/rss/articles/CBMi2AJBVV95cUxQeWRFeXVTbWpjQ1ZGM29BMGx1dGY3eFRXXzBIS3kyNkpqcEZxbV9XMkN5TXRFcXd4a2kyTjhHeVZpYVRhUWVyWkJhRmsyaEVWbW5WNm5OT2xJcTdzV2FfMmhkM1RVRy0xRUNwcnNEckhiUXQtdEczaWUyUmhVaXFoU01CTDdsWVVSN2hIbn…
DSU — Frequently Asked Questions
What is the current share price of DSU?
As of 2026-10-23 16:27 PDT, DSU trades at $8.52 on NASDAQ/NYSE. Its 52-week range is $8.52 to $9.42.
What is the market capitalisation of DSU?
DSU has a market capitalisation of $530.28M on NASDAQ/NYSE.
What is the P/E ratio of DSU?
DSU trades at a trailing price-to-earnings (P/E) ratio of 9.26. Its price-to-book (P/B) ratio is 0.84.
What is the return on equity (ROE) of DSU?
DSU has a return on equity (ROE) of 6.14%.
Is DSU a good stock to buy?
This page provides a data-driven analysis of DSU, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.